Your browser is no longer supported. Please, upgrade your browser.
Settings
ESPR Esperion Therapeutics, Inc. daily Stock Chart
ESPR [NASD]
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.54 Insider Own2.40% Shs Outstand26.15M Perf Week-3.31%
Market Cap1.07B Forward P/E- EPS next Y-2.42 Insider Trans21.69% Shs Float24.31M Perf Month-5.19%
Income-201.80M PEG- EPS next Q0.79 Inst Own- Short Float22.35% Perf Quarter-6.87%
Sales- P/S- EPS this Y-8.10% Inst Trans0.24% Short Ratio10.37 Perf Half Y-17.97%
Book/sh2.95 P/B13.88 EPS next Y37.50% ROA-104.50% Target Price85.54 Perf Year-45.38%
Cash/sh5.20 P/C7.87 EPS next 5Y28.10% ROE-134.30% 52W Range33.06 - 77.00 Perf YTD-11.00%
Dividend- P/FCF- EPS past 5Y-17.90% ROI- 52W High-46.83% Beta2.11
Dividend %- Quick Ratio2.20 Sales past 5Y- Gross Margin- 52W Low23.84% ATR2.15
Employees76 Current Ratio2.20 Sales Q/Q- Oper. Margin- RSI (14)44.08 Volatility4.53% 4.53%
OptionableYes Debt/Eq0.00 EPS Q/Q-55.10% Profit Margin- Rel Volume1.65 Prev Close40.10
ShortableYes LT Debt/Eq0.00 EarningsMar 12 BMO Payout- Avg Volume524.04K Price40.94
Recom2.10 SMA20-2.22% SMA50-8.41% SMA200-11.11% Volume863,731 Change2.09%
Mar-13-19Upgrade JP Morgan Underweight → Neutral $38 → $47
Jan-07-19Reiterated Needham Strong Buy $94 → $114
Dec-13-18Initiated Goldman Sell $45
Oct-29-18Upgrade Northland Capital Market Perform → Outperform
Oct-16-18Initiated BTIG Research Buy $82
Aug-17-18Upgrade Citigroup Neutral → Buy
Jul-11-18Downgrade Northland Capital Outperform → Market Perform
May-03-18Downgrade JP Morgan Neutral → Underweight $41
May-02-18Downgrade BofA/Merrill Buy → Underperform
Mar-27-18Reiterated Chardan Capital Markets Neutral $75 → $100
Feb-21-18Reiterated Needham Strong Buy $81 → $94
Jan-22-18Downgrade Citigroup Buy → Neutral
Jan-18-18Initiated Credit Suisse Outperform $103
Jan-17-18Reiterated UBS Buy $62 → $88
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Dec-14-17Upgrade Needham Buy → Strong Buy $72 → $81
Dec-06-17Reiterated Chardan Capital Markets Neutral $20 → $75
Aug-29-17Initiated Northland Capital Outperform $72
Aug-11-17Resumed BofA/Merrill Neutral
Aug-09-17Upgrade Jefferies Hold → Buy
Apr-07-19 10:45PM  Weekly CEO Buys Highlight GuruFocus.com
Apr-02-19 04:30PM  Esperion to Present at the Needham & Company 18th Annual Healthcare Conference GlobeNewswire +8.04%
Apr-01-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $200,000 of Shares GuruFocus.com
04:15PM  Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results GlobeNewswire
Mar-30-19 09:30AM  Esperion Therapeutics (ESPR) Down 12.9% Since Last Earnings Report: Can It Rebound? Zacks
Mar-21-19 07:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $217,400 of Shares GuruFocus.com
Mar-18-19 09:20AM  Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions GlobeNewswire
Mar-14-19 09:15PM  Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $243,650 of Shares GuruFocus.com -8.47%
Mar-13-19 05:05PM  Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine GlobeNewswire +7.55%
Mar-12-19 07:19AM  Did You Miss Esperion Therapeuticss (NASDAQ:ESPR) Impressive 225% Share Price Gain? Simply Wall St.
Mar-05-19 08:25AM  New Research Coverage Highlights Advance Auto Parts, AxoGen, Encana, Federal Signal, Nelnet, and Esperion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-04-19 04:30PM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
08:00AM  Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions GlobeNewswire
Mar-01-19 09:39AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 Zacks
Feb-28-19 04:30PM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
07:00AM  Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet GlobeNewswire
Feb-22-19 05:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.39%
Jan-29-19 08:45AM  Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation GlobeNewswire
Jan-11-19 09:16AM  For Esperion Therapeutics, 2019 Could Be a Big Year Motley Fool
Jan-07-19 07:15AM  Update: Lawsuit for Investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced by Shareholders Foundation ACCESSWIRE
02:00AM  Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet PR Newswire
Jan-06-19 10:00AM  All the Pre-JPM News Healthcare Investors Need to Know Motley Fool
Jan-04-19 04:34PM  Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today Motley Fool -6.12%
07:20AM  Esperion to receive $300 million in upfront payments in deal with Daiichi Sankyo MarketWatch
07:00AM  Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe GlobeNewswire
Jan-02-19 04:15PM  Esperion to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-18 10:28PM  Is Esperion Therapeutics, Inc. (ESPR) A Good Stock To Buy? Insider Monkey
Nov-14-18 08:52AM  Do Options Traders Know Something About Esperion (ESPR) Stock We Don't? Zacks -7.42%
Nov-10-18 08:15AM  Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018 GlobeNewswire
Nov-09-18 07:50AM  Report: Exploring Fundamental Drivers Behind American Vanguard, Pioneer Natural Resources, American States Water, Groupon, Esperion Therapeutics, and Paylocity Holding New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -6.79%
Nov-08-18 08:44AM  What's Next for Esperion Therapeutics' Cholesterol-Lowering Drug Motley Fool
08:00AM  Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
06:00AM  3 Biotech Stocks Poised for Big Rebounds Investopedia
Nov-01-18 04:05PM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results GlobeNewswire +9.93%
Oct-31-18 02:27PM  Esperion CEO on safety of new cholesterol drug CNBC Videos +6.44%
Oct-29-18 07:43AM  Esperion stock surges 15% on late-stage results for cholesterol drug MarketWatch
Oct-28-18 05:10PM  Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results GlobeNewswire
05:00PM  Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid GlobeNewswire
Oct-26-18 08:00AM  Today's Research Reports on Trending Tickers: Gilead Sciences, Inc. and Esperion Therapeutics, Inc. ACCESSWIRE +13.22%
Oct-20-18 07:01AM  3 Top Healthcare Stocks to Buy in October Motley Fool
Oct-18-18 05:00PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-17-18 08:10AM  New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-09-18 08:45AM  Do Options Traders Know Something About Esperion (ESPR) Stock We Don't? Zacks
Sep-13-18 08:52AM  Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock? Zacks
Sep-02-18 09:33AM  3 Biotech Stocks That Could Soar in September Motley Fool
Aug-28-18 10:27AM  Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol Zacks
Aug-27-18 10:22AM  Esperion's combo therapy lowers cholesterol level by 35 pct, shares surge Reuters
08:11AM  Esperion announces positive results for cholesterol-lowering therapy MarketWatch
07:32AM  Esperion says combo therapy lowers cholesterol level by 35 pct Reuters
07:00AM  Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study GlobeNewswire
Aug-26-18 03:40PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results Benzinga
Aug-25-18 05:45AM  Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress GlobeNewswire
Aug-23-18 08:42AM  Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock? Zacks
Aug-20-18 07:45AM  Market Trends Toward New Normal in Esperion Therapeutics, Oxford Immunotec Global, Limoneira, R1 RCM, Carbonite, and Shenandoah Telecommunications Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Aug-19-18 12:00PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Earnings Benzinga
Aug-13-18 09:00PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Aug-10-18 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-02-18 07:51AM  Esperion Therapeutics: 2Q Earnings Snapshot Associated Press +6.64%
07:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-16-18 07:45AM  Insider Buys Of The Week: Energen, Esperion Therapeutics And International Flavors Benzinga
Jul-10-18 08:55AM  Options Traders Expect Huge Moves in Esperion Therapeutics (ESPR) Stock Zacks -5.27%
Jul-06-18 10:51AM  UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ESPR, ORA, MFGP, FLR, and REPH GlobeNewswire
Jul-05-18 05:23PM  Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm GlobeNewswire
04:35PM  DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
02:00PM  CLASS ACTION UPDATE for ESPR, SYMC, and PPG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
08:00AM  24 HOUR DEADLINE NOTICE: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm Business Wire
Jul-03-18 02:40PM  FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire +7.78%
08:30AM  Esperion to Host Analyst and Investor Day Event on July 10 GlobeNewswire
Jul-02-18 04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR ACCESSWIRE
04:16PM  DEADLINE REMINDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
01:22PM  Beaten-down biotech stocks Gilead, Esperion are ready for a bounce MarketWatch
01:03PM  SHAREHOLDER ALERT LC ESPR INWK FLEX KLIC SYMC MFGP FLR REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
09:20AM  KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for Esperion Therapeutics, Inc. Investors - ESPR ACCESSWIRE
08:00AM  FINAL DEADLINE NOTICE: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm GlobeNewswire
Jun-30-18 11:00AM  FINAL DEADLINE ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm ACCESSWIRE
09:28AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR ACCESSWIRE
Jun-29-18 01:58PM  CLASS ACTION UPDATE for ESPR, PPG and PCG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:30PM  DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Jun-28-18 06:38PM  KESSLER TOPAZ MELTZER & CHECK, LLP: Important Deadline Reminder for Esperion Therapeutics, Inc. Investors ACCESSWIRE
04:46PM  UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LC, ESPR, and MFGP GlobeNewswire
02:40PM  IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
10:34AM  SHAREHOLDER ALERT MOH ESPR PPG ANW QCOM UNM COOL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Jun-27-18 01:30PM  INVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:30PM  UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INWK, ESPR, PRTA, and PPG GlobeNewswire
Jun-26-18 02:30PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:54PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 ESPR GlobeNewswire
Jun-25-18 12:10PM  ESPR ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR ACCESSWIRE
Jun-24-18 02:00PM  SHAREHOLDER ALERT: ALGT ESPR FLEX PPG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Jun-23-18 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline ESPR GlobeNewswire
Jun-22-18 03:30PM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:00PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 - ESPR ACCESSWIRE
Jun-21-18 04:09PM  ESPR NOTICE: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important Upcoming Deadline in Class Action ESPR GlobeNewswire -8.86%
01:50PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 - ESPR ACCESSWIRE
07:25AM  Stock Performance Review on Exelixis and Three Other Biotech Stocks ACCESSWIRE
Jun-20-18 06:25PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR ACCESSWIRE
04:34PM  Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. on Behalf of Investors ACCESSWIRE
Jun-19-18 04:00PM  SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Molina Healthcare, Inc., Esperion Therapeutics, Inc., PPG Industries, Inc., Prothena Corporation, and Fluor Corporation GlobeNewswire
10:00AM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) & Lead Plaintiff Deadline - July 6, 2018 GlobeNewswire
Jun-18-18 05:13PM  The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of Shareholders of Molina Healthcare, Inc., Esperion Therapeutics, Inc., Kulicke and Soffa Industries, Inc., and PPG Industries, Inc. GlobeNewswire
04:00PM  Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm ACCESSWIRE
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAYLEBEN TIMOTHY MPresident & CEOMar 29Buy40.005,000200,00061,163Apr 01 04:41 PM
MAYLEBEN TIMOTHY MPresident & CEOMar 20Buy43.485,000217,40056,163Mar 21 05:01 PM
VITULLO NICOLEDirectorMar 19Sale44.7315,329685,5960Mar 21 09:02 AM
MAYLEBEN TIMOTHY MPresident & CEOMar 14Buy48.735,000243,65051,163Mar 14 04:57 PM
BIOTECH TARGET N V10% OwnerMar 14Buy49.8950,0002,494,3553,522,964Mar 15 07:50 PM
NEWTON ROGER SDirectorMar 12Sale50.0625,0001,251,500548,726Mar 14 04:57 PM
BIOTECH TARGET N V10% OwnerJan 04Buy41.2980,0003,303,2563,472,964Jan 07 05:10 PM
BIOTECH TARGET N V10% OwnerDec 24Buy39.9150,0001,995,7253,392,964Dec 26 11:44 AM
BIOTECH TARGET N V10% OwnerDec 17Buy47.7360,0002,864,0703,342,964Dec 19 01:14 PM
Boxer Capital, LLC10% OwnerNov 05Sale57.1660,0003,429,8431,101,250Nov 05 07:56 PM
Boxer Capital, LLC10% OwnerNov 02Sale55.2140,0002,208,5001,161,250Nov 05 07:56 PM
NEWTON ROGER SDirectorNov 02Sale50.7622711,523573,726Nov 02 05:00 PM
NEWTON ROGER SDirectorNov 01Sale50.012,600130,026573,953Nov 02 05:00 PM
NEWTON ROGER SDirectorOct 18Sale50.001005,000576,553Oct 18 05:05 PM
NEWTON ROGER SDirectorOct 17Sale50.0212,673633,903576,653Oct 18 05:05 PM
NEWTON ROGER SDirectorOct 16Sale50.019,400470,094589,326Oct 18 05:05 PM
NEWTON ROGER SDirectorAug 27Sale51.0517,700903,610598,726Aug 29 04:56 PM
NEWTON ROGER SDirectorAug 17Sale50.067,300365,438616,426Aug 22 07:18 AM
BIOTECH TARGET N V10% OwnerAug 03Buy46.1450,0002,306,9703,282,964Aug 06 03:23 PM
BIOTECH TARGET N V10% OwnerJul 12Buy41.7750,0002,088,3003,232,964Jul 13 11:45 AM
BIOTECH TARGET N V10% OwnerJun 29Buy39.4850,0001,973,8053,182,964Jul 03 11:55 AM
BIOTECH TARGET N V10% OwnerJun 21Buy38.5760,0002,314,2243,132,964Jun 25 12:43 PM
BIOTECH TARGET N V10% OwnerJun 07Buy37.7960,0002,267,2923,072,964Jun 11 02:59 PM
GOLDSTEIN DOV A MDDirectorJun 06Option Exercise16.4713,000214,10013,047Jun 08 05:08 PM
BIOTECH TARGET N V10% OwnerJun 05Buy38.4760,0002,308,4403,012,964Jun 07 02:34 PM
BIOTECH TARGET N V10% OwnerMay 21Buy38.7780,0003,101,7602,952,964May 22 03:49 PM
BIOTECH TARGET N V10% OwnerMay 18Buy42.2450,0002,112,0102,872,964May 22 03:49 PM